A growing number of clinically unique disease-modifying therapies (DMTs) have been approved for the treatment of relapsing forms of multiple sclerosis , the most prevalent form of MS. Nevertheless, all approved drugs have clinical shortcomings in terms of efficacy, safety, tolerability, and/or delivery, creating opportunities for new and improved DMTs, be they incremental or pioneering. This content provides quantitative insight into U.S. and European physicians’ perceptions of key treatment drivers and goals in the management of relapsing MS and the current level of unmet need in this area. We analyze the commercial opportunities and how new / emerging novel and next-generation compounds may capitalize on these opportunities.
QUESTIONS ANSWERED
What are the treatment drivers and goals for relapsing forms of MS?
What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
How do current therapies perform on key treatment drivers and goals?
What are the prevailing areas of unmet need and opportunity in relapsing MS?
What trade-offs across different clinical attributes and price are acceptable to U.S. and European neurologists for a hypothetical new drug for relapsing MS?
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.